PDF(Sci-hub)
Abstract：
Genotype MTBDRsl [SL-LPA] was endorsed as a tool for early diagnosis of fluoroquinolones (FQ) and injectable second-line TB drugs (SLID) resistance in DR-TB. Correlation between specific genetic mutations using this tool and clinical outcome has not hitherto been studied in India. We conducted a observational cohort study to evaluate the predictive value of specific mutations for bad outcome. Our study identified 15 different types of gyrA mutations, commonest being A90V and D94G. Poor outcome was associated with mutations D94G and D94N/D94Y.Most XDR-TB patients harbored the high risk mutation of A1401G. Hence information of specific mutations using SL-LPA can help prognosticate and design appropriate treatment regimens.
摘要：
基因型MTBDRsl[SL-LPA]被认可为DR-TB中氟喹诺酮(FQ)和可注射二线TB药物(SLID)耐药性的早期诊断工具。迄今为止，印度尚未研究使用该工具的特定基因突变与临床结果之间的相关性。我们进行了一项观察性队列研究，以评估特定突变对不良结局的预测价值。我们的研究确定了15种不同类型的gyrA突变，最常见的是A90V和D94G。不良结果与突变D94G和D94N/D94Y相关。大多数XDR-TB患者携带A1401G的高风险突变。因此，使用SL-LPA的特定突变信息可以帮助预测和设计适当的治疗方案。
